2021 Cansino Biologics Inc(688185) biosocial Responsibility Report
Speech by the chairman of Cansino Biologics Inc(688185) biosocial responsibility report in 2021
Chairman’s speech
Help local people build an immune defense line. Our staff always go deep into the front line, cooperate slightly, complement each other’s advantages, and accelerate the industrialization of vaccines.
Not afraid of hardship and difficulty, cooperate with various parties to make the vaccine appear where it is most needed
Place. In the process of moving forward, we have also received praise from many people. Company kweisa ® The analysis results of global multicenter phase III clinical trials were successful. In the lancet, we continue to deepen our understanding of vaccine accessibility. As long as it can improve vaccine release. Partners such as the National Institutes of health of Pakistan thank us for taking care that 2021 is an extraordinary year for Cansino Biologics Inc(688185) biology. In the face of accessibility and convenience, we all actively try. The company integrates technical guidance and technical assistance. Since February 2022, kweisa ® With the approval of the sudden covid-19 pneumonia epidemic, the company has established its advantages in the covid-19 vaccine project and extended the storage advantages of Ebola vaccine to one year after covid-19 vaccine products will become the first adenovirus carrier approved for sequential booster immunization in China, On February 1, 2021, we successfully passed the approval of the State Council to realize the stable preservation of 2 ~ 8 ℃. We strengthened the covid-19 vaccine with material suppliers, and then successively approved the new linkage launched by the independent data monitoring committee (IDMC) composed of international experts in Malaysia and Indonesia, so as to improve the stability of material supply and strengthen immunization with third-party logistics companies in sequence. A shot of effective kweisa ® Good news spreads frequently.
Phase III clinical efficacy evaluation of coronavirus vaccine. At that moment, I knew that the company had cooperated for many years to build a nationwide vaccine cold chain logistics distribution system to ensure timely delivery
The accumulated core technology route has successfully become an effective global public delivery. In the future, Cansino Biologics Inc(688185) biology will continue to lead China’s innovative vaccines to truly walk the health and immune shield. On February 25, 2021, covid-19 vaccine of the company was released to the international market to better undertake corporate social responsibility.
Not forgetting the original intention, we worked hard and obtained the approval of the State Food and Drug Administration for listing with conditions. In this battle with covid-19 epidemic, we gathered together to shoulder the mission and forge ahead. The company adheres to Party building. We will use the most economical, effective and high-quality vaccine to block infectious diseases. We have won a phased victory in the 400 day race. Lead, constantly improve the governance structure and strictly control risks. The company pays attention to suppliers and makes modest efforts to build a community with a healthy future for mankind.
Deliver quality, environmental performance and social responsibility, and comprehensively lead the joint construction of suppliers
Sustainable supply chain.
We are eager for talents, continue to promote the talent development strategy, and gather the world’s outstanding chairman and CEO of Cansino Biologics Inc(688185) biology. Health, hope and commitment are the original intention of Cansino Biologics Inc(688185) biology and the first year Cansino Biologics Inc(688185) went to the large-scale production of covid-19 vaccine. The origin of the name of Jianyu Xuefeng. As an innovative vaccine company, we hold the concept of “health for all” from a global perspective and refer to the United Nations sustainable development goals. The company stimulates the potential of employees and comprehensively opens up the promotion of diversified employees
Tao, care for the growth and health of all “healthy families” and go to the future with employees. On March 25, 2022, we will unswervingly develop, produce and supply high-quality vaccine products. In 2021, (sdgs) calls for a better corporate society for people all over the world
Company’s Ad5 ncov kweisa ® It has become the first approved answer sheet of adenovirus loading responsibility in China. We actively give back to society, make vaccines universal and improve human health and well-being,
Covid-19 vaccine. The bivalent meningitis vaccine mcv2 developed by the company helps alleviate poverty and promote rural revitalization. Every “Kang family” strives to be the most beautiful
happiness ® And China’s first tetravalent meningitis vaccine MCV4 manhaixin ® Based on the five major technology platforms, we are racing against time to promote research and development, so that safe, effective and retrograde people can rush to the disaster area and help each other in the same boat.
After the recombinant Ebola virus vaccine Ad5 EBOV, it has become a high-quality vaccine product to protect human health. In kweisa ® After successful approval,
The core technical team of the company invested in the mucosal immunization of Ad5 ncov for the first time, and Cansino Biologics Inc(688185) organisms reaped all kinds of warmth. In the party and
New contributions to global public health.
In the process of research and development, we hope to use innovative inhalation drug delivery methods to achieve better results under the leadership of the state and the leadership of governments at all levels in Tianjin and Shanghai
As a company that brings together senior experts in the global vaccine industry, Cansino Biologics Inc(688185) biological protection effect. With strong support, the company completed the project at an incredible “China speed”
Things are leading in technology. However, as a returned entrepreneur, I have been involved in the R & D, clinical, marketing, production and transportation of three vaccines. I
The co founders knew that on the road of the company’s development, Cansino Biologics Inc(688185) biology carried out covid-19 vaccine production for Mexico and with the strong support of governments of many developing countries while orderly promoting vaccine production in China
But young. 2021 is the 12th year of the company’s development. It is also the year when we fully provide technical assistance to Pakistan, Malaysia and other developing countries and cooperate with foreign filling production lines. We compete with many top research institutions outside China
About Cansino Biologics Inc(688185)
